Table 1.
Model inputs for treatment and monitoring frequencies and data sources for baseline BCVA the base-case scenario
| Time period | Treatment | BCVA data source | Mean number of treatments administered | Mean number of monitoring visits |
|---|---|---|---|---|
| Year 1 | Ranibizumab | RADIANCE study (0–12 months) [23] | 3.5 [23] | 8.5a (assumption) |
| vPDT |
RADIANCE study (0–3 months) [23] VIP trial (4–12 months) [5] |
3.4 [5] | 4.0 [48] | |
| Observation | VIP trial (0–12 months) [5] | 0 | 4.0 [5] | |
| Year 2 | Ranibizumab | Natural history [30] | 1.0b (expert advice) | 4.0 (assumption) |
| vPDT | Natural history [30] | 1.7 (VIP trial) [6] | 4.0 [48] | |
| Observation | Natural history [30] | 0 | 4.0 (assumption) | |
| Year 3+ | Ranibizumab | Natural history [30] | 0b (expert advice) | 0b (expert advice) |
| vPDT | Natural history [30] | 0 (VIP trial) [6] | 0 (VIP trial) [6] | |
| Observation | Natural history [30] | 0 | 4.0 (assumption)c |
BCVA best-corrected visual acuity, mCNV myopic choroidal neovascularization, RADIANCE Ranibizumab and vPDT Evaluation in Myopic Choroidal Neovascularization, SmPC Summary of Product Characteristics, VIP Verteporfin in Photodynamic Therapy, vPDT verteporfin photodynamic therapy
aThis is a conservative assumption; the ranibizumab SmPC states that about 5.5 monitoring visits are expected in year 1 of ranibizumab treatment
bExpert advice was taken from an advisory board of 11 UK ophthalmologists
cFor patients undergoing observation, as the disease is not actively being treated it was assumed that they will continue to be monitored up to year 3, as their disease was unlikely to have been cured. For patients receiving treatment, in the absence of long-term data, and informed by expert advice, it was assumed that mCNV has a limited course, requiring no monitoring visits in year 3